This unprecedented achievement is attributed to the resounding success of mdbrain . We were able to showcase remarkable efficiency gains and quality improvements with our established neuroradiological solution. The ascent of AI Diagnostics as a self-paid patient service has further propelled our success.

mdprostate as a new driver for growth

The pinnacle of our success in 2023 was the launch of mdprostate in the third and fourth quarters. In a mere two months, we seamlessly deployed mdprostate to over 10% of our existing client base and welcomed a host of new clients. This triumph is merely the beginning. With the upcoming version promising even greater performance, we are anticipating a strong market pull for 2024.

Strategic Partnerships and Global Expansion

Integral to our success story are strategic partnerships with industry leaders like Angionautix, Bender, Bayer/Calantic, DeepC, Medecon, Sectra, Supermedical, and others. These robust alliances have not only strengthened our international business but have also played a pivotal role in our global expansion strategy.

2024 will be characterized by international scaling and expansion of the product portfolio

Looking ahead to 2024, Mediaire envisions another dynamic year. Our CEO, Dr. Andreas Lemke, comments on what's ahead as follows: 'We plan to extend both our direct commercial activities and joint ventures with partners, along with a substantial expansion of our product portfolio. Exciting developments are on the horizon as we explore new areas where AI can deliver substantial value for radiologists. Our unwavering commitment remains focused on ensuring seamless integration and a positive cost-benefit scenario for our solutions.